An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease
Open accessAbstract
Background Most patients with atherosclerotic cardiovascular disease fail to achieve guideline-directed low-density lipoprotein cholesterol (LDL-C) goals. Twice-yearly inclisiran lowers LDL-C by ∼50% when added to statins. Objectives This study evaluated the effectiveness of an "inclisiran first" implementation strategy (adding inclisiran immediately upon failure to reach LDL-C Methods VICTORION-INITIATE, a prospective, pragmatically designed trial, randomized patients 1:1 to inclisiran (284 mg at days 0, 90, and 270) plus usual care (lipid management at treating physician's discretion) vs usual care alone. Primary endpoints were percentage change in LDL-C from baseline and statin discontinuation rates. Results We randomized 450 patients (30.9% women, 12.4% Black, 15.3% Hispanic); mean baseline LDL-C was 97.4 mg/dL. The "inclisiran first" strategy led to significantly greater reductions in LDL-C from baseline to day 330 vs usual care (60.0% vs 7.0%; P Conclusions An "inclisiran first" implementation strategy led to greater LDL-C lowering compared with usual care without discouraging statin use or raising new safety concerns. (A Randomized, Multicenter, Open-label Trial Comparing the Effectiveness of an "Inclisiran First" Implementation Strategy to Usual Care on LDL Cholesterol [LDL-C] in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C [≥70 mg/dL] Despite Receiving Maximally Tolerated Statin Therapy [VICTORION-INITIATE]; NCT04929249).
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The comparative advantage of inclisiran over statins, combined with biannual dosing, supports its potential to improve lipid management and treatment adherence in clinical practice.
“This comparative advantage, combined with inclisiran’s biannual dosing regimen, supports its potential to improve both lipid management and treatment adherence in clinical practice.12”
From Small Interfering RNA for LDL-Cholesterol Reduction (2026) · cites this paper as [12]
VICTORION-INITIATE head-to-head evidence demonstrates that inclisiran provides superior LDL-C lowering compared to standard statin therapy in certain patient populations.
“This head-to-head evidence demonstrates that inclisiran not only significantly reduces LDL-C compared to placebo but also provides superior LDL-C lowering compared to standard statin therapy in certain patient populations.”
From Small Interfering RNA for LDL-Cholesterol Reduction (2026) · cites this paper as [12]
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961 · see citing works
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550 · see citing works
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · see citing works
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854 · see citing works
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487 · see citing works
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962 · see citing works
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634 · see citing works
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691 · see citing works
The Hawthorne Effect: a randomised, controlled trial
McCarney, R., Warner, J. P., Iliffe, S., van Haselen, R. A., Griffin, M., & Fisher, P. (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-30 · Cited by 1,730 · see citing works
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665 · see citing works
Ray, K. K., Molemans, B., Schoonen, W. M., Giovas, P., Bray, S., Kiru, G., Murphy, J., Banach, M., De Servi, S., Gaita, D., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa047 · Cited by 839 · see citing works
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., II, Goldstein, L. B., Chin, C. C., Tannock, L. R., Miller, M. J., Raghuveer, G., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 760 · see citing works
Lloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Covington, A. M., DePalma, S. M., Minissian, M. B., Orringer, C. E., Smith, S. C., Waring, A. A., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.07.006 · Cited by 569 · see citing works
Impact of Lipids on Cardiovascular Health
Ference, B. A., Graham, I., Tokgozoglu, L., & Catapano, A. L. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.046 · Cited by 511 · see citing works
Long-term evolocumab in patients with established atherosclerotic cardiovascular disease
O’Donoghue, M. L., Giugliano, R. P., Wiviott, S. D., Atar, D., Keech, A., Kuder, J. F., Im, K., Murphy, S. A., Flores-Arredondo, J. H., López, J. A. G., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.061620 · Cited by 410 · see citing works
Ray, K. K., Haq, I., Bilitou, A., Manu, M. C., Burden, A., Aguíar, C., Arca, M., Connolly, D. L., Eriksson, M., Ferrières, J., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100624 · Cited by 353 · see citing works
Wiviott, S. D., Cannon, C. P., Morrow, D. A., Ray, K. K., Pfeffer, M. A., & D, E. B. M. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.04.064 · Cited by 340 · see citing works
Rodríguez, F., Maron, D. J., Knowles, J. W., Virani, S. S., Lin, S., & Heidenreich, P. A. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2018.4936 · Cited by 339 · see citing works
Ray, K. K., Troquay, R. P. T., Visseren, F. L. J., Leiter, L. A., Scott Wright, R., Vikarunnessa, S., Talloczy, Z., Zang, X., Maheux, P., Lesogor, A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00353-9 · Cited by 328 · see citing works
Koren, M. J., & Hunninghake, D. B. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.053 · Cited by 286 · see citing works
Self-citationCannon, C. P., de Lemos, J. A., Rosenson, R. S., Ballantyne, C. M., Liu, Y., Gao, Q., Palagashvili, T., Alam, S., Mues, K. E., Bhatt, D. L., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.1810 · Cited by 245 · see citing works
Wright, R. S., Ray, K. K., Raal, F. J., Kallend, D. G., Jaros, M., Koenig, W., Leiter, L. A., Landmesser, U., Schwartz, G. G., Friedman, A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.058 · Cited by 229 · see citing works
Cheeley, M. K., Saseen, J. J., Agarwala, A., Ravilla, S., Ciffone, N., Jacobson, T. A., Dixon, D. L., & Maki, K. C. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2022.05.068 · Cited by 197 · see citing works
Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs
Khvorova, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1614154 · Cited by 184 · see citing works
Koren, M. J., & Hunninghake, D. B. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.12.117 · Cited by 130 · see citing works
Self-citationNavar, A. M., Wang, T. Y., Li, S., Robinson, J. G., Goldberg, A. C., Virani, S., Roger, V. L., Wilson, P. W. F., Elassal, J., Lee, L. V., et al. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.08.005 · Cited by 94 · see citing works
Toth, P. P., Granowitz, C. B., HULL, M. L., Anderson, A. J., & Philip, S. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1099-z · Cited by 89 · see citing works
Self-citationSafety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials
Wright, R. S., Köenig, W., Landmesser, U., Leiter, L. A., Raal, F. J., Schwartz, G. G., Lesogor, A., Maheux, P., Stratz, C., Zang, X., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.007 · Cited by 84 · see citing works
Underberg, J. A., Toth, P. P., & Rodríguez, F. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2117498 · Cited by 80 · see citing works
Self-citationSchroff, P., Gamboa, C. M., Durant, R. W., Oikeh, A., Richman, J., & Safford, M. M. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005449 · Cited by 76 · see citing works
Virani, S. S., Woodard, L., Chitwood, S. S., Landrum, C. R., Urech, T. H., Wang, D., Murawsky, J., Ballantyne, C. M., & Petersen, L. A. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.07.013 · Cited by 56 · see citing works
Gu, J., Sanchez, R. J., Chauhan, A., Fazio, S., & Wong, N. D. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100336 · Cited by 54 · see citing works
Virani, S. S., Kennedy, K. F., Akeroyd, J. M., Morris, P. B., Bittner, V. A., Masoudi, F. A., Stone, N. J., Petersen, L. A., & Ballantyne, C. M. (2018) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.004652 · Cited by 53 · see citing works
May, H. T., Knowlton, K. U., Anderson, J. L., LAPPE, D. L., Bair, T. L., & Muhlestein, J. B. (2021) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcab024 · Cited by 30 · see citing works
Landmesser, U., McGinniss, J., Steg, P. G., Bhatt, D. L., Bittner, V., Díaz, R., Dilić, M., Goodman, S. G., Jukema, J. W., Loy, M., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac107 · Cited by 17 · see citing works
Flagged first, then by citations
2 of the 37 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Palaniappan, L. P., Allen, N. B., Almarzooq, Z., Anderson, C. A. M., Arora, P. K., Avery, C. L., Baker-Smith, C. M., Bansal, N., Currie, M. E., Earlie, R. S., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001412 · Cited by 312 · see citing works
An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia
Koren, M. J., Vega, R. B., Agrawal, N., Xu, Y., Barbour, A., Yu, H., Wallerstedt, E., Carter, D., Middlemiss, J. E., Twaddle, L., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.499 · Cited by 76 · see citing works
Self-citationBanach, M., Reiner, Ž., Surma, S., Bajraktari, G., Bielecka-Dabrowa, A. M., Bunc, M., Bytyçi, I., Češka, R., Cicero, A. F. G., Dudek, D., et al. (2024) · Drugs · doi:10.1007/s40265-024-02105-5 · Cited by 76 · see citing works
Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
Safarova, M. S., Bimal, T., Soffer, D. E., Hirsh, B. J., Shapiro, M. D., Mintz, G. L., Cha, A., & Gianos, E. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100701 · Cited by 52 · see citing works
Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field
Barbagallo, F. D. G., Andreychuk, N., Scicali, R., González-Lleó, A. M., Piro, S., Masana, L., & Ibarretxe, D. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01271-x · Cited by 32 · see citing works
Real-World Efficacy and Safety of Inclisiran
Gargiulo, P., Marzano, F., Crisci, M., Marcucci, R., Bruzzese, D., Maloberti, A., Sarullo, F. M., Galasso, G., Indolfi, C., Musumeci, G., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.10.106 · Cited by 28 · see citing works
Heo, K., Phan, L. P., Le, N. T. T., & Jin, Y. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01542-4 · Cited by 29 · see citing works
Zhang, S., Sun, L., Xu, X., Zhang, Y., & Chen, Q. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04321-z · Cited by 22 · see citing works
Current usage of inclisiran for cardiovascular diseases: overview of current clinical trials
Harbi, M. H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1449712 · Cited by 20 · see citing works
A Hitchhiker's Guide to long-read genomic analysisPreprint
Mahmoud, M., Agustinho, D. P., & Sedlazeck, F. J. (2025) · Genome Research · doi:10.1101/gr.279975.124 · Cited by 20 · see citing works
Girolamo, F. G. D., Pellin, L., Roni, C., Biolo, G., Sinagra, G., & Fabris, E. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106442 · Cited by 16 · see citing works
Sheth, S., Banach, M., & Toth, P. P. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2398444 · Cited by 14 · see citing works
Self-citationNew pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024
Tamargo, J. L., Agewall, S., Ambrosio, G., Borghi, C., Cerbai, E., Dan, G. A., Drexel, H., Ferdinándy, P., Grove, E. L., Klingenberg, R., et al. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf012 · Cited by 16 · see citing works
Engineered extracellular vesicles as nanosponges for lysosomal degradation of PCSK9
Wang, C., Zhou, X., Bu, T., Liang, S., Hao, Z., Qu, M., Liu, Y., Wei, M., Xing, C., Yang, G., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.034 · Cited by 13 · see citing works
Yang, C., Mo, L., Zhang, G., Dai, Y., Li, B., Tan, Z., Guo, Y., Lu, S., Hong, Y., He, H., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.09.023 · Cited by 13 · see citing works
Mansoor, T., Rao, B. H., Gupta, K., Parikh, S. S., Abramov, D., Mehta, A., Al Rifai, M., Virani, S. S., Nambi, V., Minhas, A. M. K., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00712-x · Cited by 12 · see citing works
Challenges in achieving LDL cholesterol targets and novel approaches to lipid lowering
Malick, W. A., Choi, D., Langsted, A., Bittner, V., Nordestgaard, B. G., Stroes, E. S. G., & Rosenson, R. S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf123 · Cited by 12 · see citing works
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 45 · see citing works
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy
Nicholls, S. J., & Nelson, A. J. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01280-4 · Cited by 12 · see citing works
Basit, J., Ahmed, M., Singh, P., Ahsan, A., Zulfiqar, E., Iqbal, J., Fatima, M., Upreti, P., Hamza, M., & Alraies, M. C. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70039 · Cited by 10 · see citing works
Khalil, I., Rahman, M. T., & Hossain, I. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.04.013 · Cited by 8 · see citing works
Quagliariello, V., Berretta, M., Bisceglia, I., Iovine, M., Barbato, M., Arianna, R., Canale, M. L., Paccone, A., Inno, A., Scherillo, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146617 · Cited by 10 · see citing works
Mulligan, M. D., Gandhi, R. S., Vishwakarma, R., & Bhattacharya, R. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.03.019 · Cited by 8 · see citing works
Surma, S., Shapiro, M. D., & Banach, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107246 · Cited by 9 · see citing works
Global Burden of Elevated LDL-C
Collaborators, G. 2. L. C., Razo, C., DeCleene, N. K., Johnson, C. O., Stark, B. A., LeGrand, K. E., Aalruz, H., Abaraogu, U. O., ElHafeez, S. A., Abdelmasseh, M., et al. (2026) · JAMA · doi:10.1001/jama.2026.8628 · Cited by 8 · see citing works
From clinical development to real-world outcomes with inclisiran
Connolly, D. L., Sharma, V., & Ray, K. K. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000954 · Cited by 7 · see citing works
Non-Coding RNA Involved in the Pathogenesis of Atherosclerosis—A Narrative Review
Kiełbowski, K., Żychowska, J., Bakinowska, E., & Pawlik, A. (2024) · Diagnostics · doi:10.3390/diagnostics14171981 · Cited by 6 · see citing works
Tang, L., Li, G., Chang, J., Xian, H., Liu, Y., Lin, L., Dai, Z., Liu, Z., Qiu, X., Zhang, B., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.010 · Cited by 6 · see citing works
Cleto, A. S., Schirlo, J. M., Gomes, V. H. O., Beraldo, M. L. J., Neiverth, G. S., Beltrame, M. L., Machozeki, J., & Martins, C. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16091 · Cited by 7 · see citing works
Gupta, K., Rawlley, B., Meloche, C., Minhas, A. M. K., Hermel, M., Slipczuk, L. N., Sheikh, S. S., Khoja, A. A., Vaughan, E. M., Dalakoti, M., et al. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01218-2 · Cited by 6 · see citing works
Maliha, M., Satish, V., Kumar, S. S., Chi, K. Y., Shama, N., Kharawala, A., Duarte, G., Li, W., Purkayastha, S., Mangeshkar, S., et al. (2025) · Healthcare · doi:10.3390/healthcare13020141 · Cited by 6 · see citing works
“Inclisiran: Early LDL-C target achievement in a real-life population”
Briani, F., Bagli, M., Venturi, G., Bacchion, F., & Mugnolo, A. (2025) · Atherosclerosis Plus · doi:10.1016/j.athplu.2025.01.001 · Cited by 5 · see citing works
Tang, Y., Zou, J., Li, Q., Liu, Y., Guo, X. D., Bai, H., He, X. D., Gan, C., Zhao, X., Wu, W., et al. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126189 · Cited by 5 · see citing works
The discovery of PCSK9 as a pivotal point in the prevention of cardiovascular disease
Razavi, A. C., & Shapiro, M. D. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101314 · Cited by 5 · see citing works
Sapina, A. I., Varlamova, Y. Y., Papyrina, M. G., Bezymyanny, A. S., Kordzaya, E. L., & Vasilyeva, E. Y. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-5943 · Cited by 5 · see citing works
Advances in Clinical Cardiology 2024: A Summary of Key Clinical Trials
Savage, P., Campbell, M., Hogg, M., McElhatton, D., & Menown, I. B. A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03220-9 · Cited by 5 · see citing works
Maidman, S. D., & Rosenson, R. S. (2025) · BioDrugs · doi:10.1007/s40259-025-00731-3 · Cited by 6 · see citing works
Long-term cardiovascular safety of inclisiran: a pooled analysis of phase 3 randomized trials
Karakasis, P., Patoulias, D., Barkas, F., Theofilis, P., Milionis, H. J., Doumas, M. N., Kassimis, G., Tsioufis, K. P., & Fragakis, N. (2024) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2024.06.005 · Cited by 5 · see citing works
Lai, P., Xu, S., Liu, Z., Ling, J., Tian, K., Yan, J., Chen, D., Zhong, Y., & Xue, J. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1474472 · Cited by 5 · see citing works
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Bertolet, B. D., Cabral, K. P., Sullenberger, L. E., McAlister, J., Sandroni, T., & Patel, D. S. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00665-1 · Cited by 4 · see citing works
Efficacy, benefit and safety of inclisiran
López-Miranda, J. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100730 · Cited by 4 · see citing works
Lupi, A., Baluci, M., Persampieri, S., Perversi, I., Presutti, D. G., Somaschini, A., Gaudio, G. V., Guasti, L., Ferrini, M., Corsini, A., et al. (2025) · Atherosclerosis Plus · doi:10.1016/j.athplu.2025.09.005 · Cited by 3 · see citing works
Knowlton, K. U., Návar, A. M., Anderson, J. L., Brown, A. S., Muhlestein, J. B., Kleeman, K., Sarwat, S., Abbas, C. A., Ramirez, M. A., Grines, C. L., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.043655 · Cited by 3 · see citing works
Self-citationTherapeutic Management of LDL-C: Efficacy and Economic Impact Assessment
Elshafeey, A. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12050196 · Cited by 3 · see citing works
Emerging Pharmacological Therapies in the Management of Hyperlipidemia
Sharma, N., & Roy, S. (2026) · Current Clinical Pharmacology · doi:10.2174/0127724328440604260225063619 · Cited by 2 · see citing works
Mafham, M., Zayed, M., Collins, R., Sabatine, M. S., Armitage, J., Brittain, D., da Costa, B. R., Chen, F., Goonasekera, M. A., Hill, M., et al. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107546 · Cited by 3 · see citing works
Mirghani, H. O., Albalawi, B. H., Alshehri, M. S., Almalawi, W. M., Alanezi, S. A., Alarki, M., Alyahya, A. A., Alshaman, S., Shaman, M. S., & Al-Anazi, A. B. (2024) · Cureus · doi:10.7759/cureus.70411 · Cited by 2 · see citing works
Alexander, G. C., Curran, J. N., Victores, A., Mehta, H. B., Lin, S., Xiao, X., Michos, E. D., Ballreich, J. M., Bash, L. D., Exter, J., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09625-0 · Cited by 2 · see citing works
Pechetty, R., Rao, P. S., Deb, T., Shekar, C., & Deepthi, K. (2025) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_55_2025 · Cited by 2 · see citing works
Early Inclisiran Use in Atherosclerotic Cardiovascular Disease
Shapiro, M. D., & German, C. A. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.03.402 · Cited by 2 · see citing works
Eficacia, beneficio y seguridad de inclisiran
López‐Miranda, J. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.07.003 · Cited by 1 · see citing works
Razavi, A. C., Sokolsky, M., Belanger, M., Blazoski, C. M., Spitz, J. A., Sperling, L. S., Blumenthal, R. S., & Whelton, S. P. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101417 · Cited by 1 · see citing works
Inclisiran in Dyslipidemia with High Residual Platelet Reactivity
Kapsultanova, D. A., Жангелова, Ш. Б., Nurmukhammad, F., Makasheva, Z., Sakhov, O., Tamara, G., Rustamova, F., Akhmentayeva, D., & Aubakirova, B. (2026) · Diseases · doi:10.3390/diseases14010030 · Cited by 1 · see citing works
Upfront Combination or Stepwise Escalation: Personalising LDL-C Reduction in Clinical Practice
Pirillo, A., & Catapano, A. L. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01400-8 · Cited by 1 · see citing works
RNA interference for lipid disorders: is this the future?
Nassif, M., Fazoli, R. T., & Generoso, G. (2026) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001033 · Cited by 1 · see citing works
Marnell, C. S., Koenig, W., Bittner, V., Watson, K. E., Muntner, P., Nordestgaard, B. G., Yan, L. L., Verbakel, M., & Rosenson, R. S. (2026) · Circulation Population Health and Outcomes · doi:10.1161/circoutcomes.125.012330 · Cited by 1 · see citing works
Fadah, K., Alomari, M., Elchouemi, M., & Lange, R. A. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02362-8 · Cited by 1 · see citing works
Biologics for cardiovascular diseases: from bench to bedside
Sun, X., Wang, X., Jia, R., Tang, J., Zeng, X. Y., Zhao, F., Zeng, F., Huang, N., Li, J., & Cui, K. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02673-w · Cited by 2 · see citing works
Li, Y., Xue, K., Hu, R., Hu, X., Guo, R., Hongxia, G., & Li, G. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00702-z · Cited by 3 · see citing works
Therapeutic Persistence in the Management of Familial Hypercholesterolemia
Lin, K. H., & Stone, N. J. (2024) · JACC Case Reports · doi:10.1016/j.jaccas.2024.102712 · Cited by 1 · see citing works
Small Interfering RNA for LDL-Cholesterol Reduction
Batista, F., Mamede, I., & Dacoregio, M. (2026) · JACC: Advances · doi:10.1016/j.jacadv.2026.102932
Widjaja, J. S., Adji, A. S., Baraja, A., Dharmasaputra, A., Rosyadi, R. N., Komalasari, I., Mustofa, A., Multazam, C. E. C. Z., Alkaff, F. F., & Saputra, P. B. T. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179420
News in cardiovascular pharmacotherapy from the ACC.24 Meeting
Caballero, R., Delpón, E., & Tamargo, J. L. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae034
Sofortige Gabe von Incliseran mit beeindruckenden Ergebnissen (VICTORION-INITIATE)
Dahm, J. B. (2024) · Aktuelle Kardiologie · doi:10.1055/a-2304-7804
Kumar, D., & Yadav, S. (2024) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_52_24
Single bolus PCSK9 Inhibition: A new approach to plaque stabilisation
Nicholls, S. J., & Manmathan, G. P. R. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.118628
V CardioMIR: el Congreso de los Jóvenes Cardiólogos
Monterde, E. M., Rodríguez, A. J. W., Duran, Ö., & Laffond, A. E. (2024) · REC CardioClinics · doi:10.1016/j.rccl.2024.10.008
Zupanc, T., Krajačič, J., Krajačič, B., Zupanc, O., & Bunc, M. (2024) · South East European Journal of Cardiology · doi:10.3889/seejca.2024.6073
Jaspan, V. N., & Shapiro, M. D. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.04.011
Demystifying the nuances of the lipid patient: a guide for primary care providers
Myerson, M. L., Gillett, K., O’Hara, J., Potter, R., & SKOLNIK, N. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101070
Wong, N. D., Karthikeyan, H., Fan, W., & Electricwala, B. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102517
Chen, Z., Ma, S., Zhang, J., Zhang, R., Zhou, M., Li, C., Chen, Y., Wang, H., & He, Y. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-112947
Piro, V., González, E. F., Romano, F., Galván, M., Fernández, Groba, M. D. V., López, M., & García, A. (2026) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2026.500949
Kwon, Y., Kim, N., Kim, D.-H., Kim, B., Park, J. S., Park, Y. J., Park, B. E., Kim, H. N., Lee, J. H., Yang, D. H., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-06087-y
Inclisiran—will it fulfill its promise?
Zadeh, S. S. T., Fogacci, F., & Hadaegh, F. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104848
PCSK9 inhibitors do not increase cognitive risk
Ni, D., Feng, Z., Liang, D., Qi, Z., Lu, Y., Zhu, L., & Li, G. (2026) · Biology Direct · doi:10.1186/s13062-026-00865-6
Cost-Effectiveness of Pitavastatin in Dyslipidemia: A Systematic Review
Vo, N. X., Pham, H. L., Bui, T. T., & Bui, T. T. (2026) · Healthcare · doi:10.3390/healthcare14131847
Ahn, C., Jeong, H., Yim, H. W., Kim, N. J., Han, S., & Oh, I. (2026) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2026.1855572
Lan, J., Qiu, Y., Wang, S., Zhang, Y., Cheng, S., Chen, S., & Xing, Y. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1853767
Hargovan, S., Hunt, N., Kostakis, H., & Chow, C. K. (2026) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2026.200687
Medication Non-Adherence in Resistant Hypertension: Detection, Drivers, and Practical Solutions
Perera, S., & Gallagher, B. D. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02410-3
- Authors
- Koren, M. J., Rodriguez, F., East, C., Toth, P. P., Watwe, V., Abbas, C. A., Sarwat, S., Kleeman, K., Kumar, B., Ali, Y., & Jaffrani, N.
- Affiliations
- Jacksonville Center for Clinical Research (US)
- Baylor Scott & White Research Institute (US)
- Johns Hopkins University (US)
- Novartis (United States) (US)
- Rapides Regional Medical Center (US)
- Corresponding author
- Koren, Michael J.
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2024-05
- Volume
- 83
- Issue
- 20
- Pages
- 1939-1952
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W4394060983
- Cited by
- 81
- References
- 37
- Citations by year
- 2026: 26 · 2025: 27 · 2024: 28
- FWCI
- 33.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- inclisiran, atherosclerotic cardiovascular disease, LDL cholesterol lowering, statin discontinuation, LDL-C goal attainment, PCSK9 inhibition, usual care, lipid control, injection-site adverse events, treatment-emergent adverse events, statin-sparing therapy
- MeSH terms
- Aged, Female, Humans, Cholesterol, LDL, Male, Middle Aged, Oligonucleotides, Prospective Studies, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
